Skip to main content

Table 4 Drug-resistant profiles of new patients stratified by age groups

From: Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study

 15–34
(n = 666)
35–59
(n = 1318)
≥60
(n = 1736)
Total
(n = 3720)
p-value
Any drug resistance91 (13.7%)189 (14.3%)230 (13.2%)510 (13.7%)0.685
Resistant to
 INH62 (9.3%)140 (10.6%)153 (8.8%)355 (9.5%)0.236
 RIF41 (6.2%)54 (4.1%)42 (2.4%)137 (3.7%)0.000
 Rfb31 (4.7%)33 (2.5%)28 (1.6%)92 (2.5%)0.000
 EMB15 (2.3%)38 (2.9%)29 (1.7%)82 (2.2%)0.077
 PZA11 (1.7%)22 (1.7%)21 (1.2%)54 (1.5%)0.514
 Km2 (0.3%)5 (0.4%)11 (0.6%)18 (0.5%)0.455
 Am2 (0.3%)5 (0.4%)10 (0.6%)17 (0.5%)0.584
 Cm3 (0.5%)5 (0.4%)15 (0.9%)23 (0.6%)0.198
 Sm26 (3.9%)46 (3.5%)59 (3.4%)131 (3.5%)0.832
 Lfx8 (1.2%)18 (1.4%)18 (1.0%)44 (1.2%)0.706
 Mfx7 (1.1%)14 (1.1%)17 (1.0%)38 (1.0%)0.971
 Ofx8 (1.2%)18 (1.4%)17 (1.0%)43 (1.2%)0.608
 Pto6 (0.9%)6 (0.5%)18 (1.0%)30 (0.8%)0.196
 Cs0 (0.0%)1 (0.1%)1 (0.1%)2 (0.1%)0.785
 PAS3 (0.5%)14 (1.1%)24 (1.4%)41 (1.1%)0.145
INH-monoresistance36 (5.4%)99 (7.5%)122 (7.0%)257 (6.9%)0.210
RIF-monoresistance15 (2.3%)13 (1.0%)11 (0.6%)39 (1.0%)0.002
Multidrug resistance26 (3.9%)41 (3.1%)31 (1.8%)98 (2.6%)0.006
Resistance to any FQsa9 (1.4%)18 (1.4%)18 (1.0%)45 (1.2%)0.666
Resistance to any SLIDsb5 (0.8%)6 (0.5%)17 (1.0%)28 (0.8%)0.252
  1. Abbreviations: INH isoniazid, RIF rifampicin, Rfb rifabutin, EMB ethambutol, PZA pyrazinamide, Km kanamycin, Am amikacin, Cm capreomycin, Sm streptomycin, Lfx levofloxacin, Mfx moxifloxacin, Ofx ofloxacin, Pto prothionamide, Cs cycloserine, PAS para-aminosalicylic acid, FQs fluoroquinolones, SLIDs second-line injectable drugs
  2. aAny fluoroquinolones refer to levofloxacin, moxifloxacin, or ofloxacin
  3. bAny second-line injectable drugs refer to kanamycin, amikacin, or capreomycin